{"id":"W2947269143","doi":"10.1200/jco.2019.37.15_suppl.4570","title":"First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pembrolizumab; Cohort; Renal cell carcinoma; Internal medicine; Clear cell renal cell carcinoma; Clinical endpoint; Oncology; Surgery; Urology; Gastroenterology; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004300484,0.0007298855,0.001118697,0.0006997255,0.00056555,0.001137933,0.0009685968,0.0007257751,0.00360223],"category_scores_gemma":[0.002194953,0.0003411984,0.001176142,0.001011565,0.0001890282,0.000836207,0.0006825114,0.001266051,0.001301363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001006324,"about_ca_system_score_gemma":0.002231343,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005090657,"about_ca_topic_score_gemma":0.01007455,"domain_scores_codex":[0.9989177,0.0003898955,0.00009066599,0.0001677332,0.0003013212,0.0001327491],"domain_scores_gemma":[0.9969857,0.0004872904,0.0007594832,0.0003128345,0.000708518,0.0007462435],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2277585,0.01307246,0.295187,0.004139999,0.01062447,0.001220041,0.0006849967,0.00370353,0.0437122,0.0007097613,0.1238042,0.2753829],"study_design_scores_gemma":[0.08619165,0.08466241,0.7163049,0.0008385628,0.009000829,0.002716827,0.000336177,0.002085884,0.008479718,0.0004784051,0.08871432,0.0001902136],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8659607,0.01385973,0.002062987,0.0009664096,0.0002903282,0.004166022,0.1035323,0.0002424952,0.008919043],"genre_scores_gemma":[0.7384627,0.00687001,0.005096575,0.002258018,0.0004058036,0.00297159,0.2390353,0.0001006481,0.004799369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005090657,"threshold_uncertainty_score":0.02274346,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06056821045133883,"score_gpt":0.3896819068824581,"score_spread":0.3291136964311193,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}